Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Seminars in Oncology
|
November 8, 2002
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures
Erick Gamelin, Laurence Gamelin, Laura Bossi, et al.
Bulletin Du Cancer
|
February 24, 2006
[Oxaliplatin neurotoxicity]
Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
International Journal of Hematology
|
April 17, 2016
Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies
Wendy J Langeberg, W Marieke Schoonen, Melissa Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 19, 2008
Recurrent priapism related to oxaliplatin infusion
Antoine Adenis, Audrey Mailliez, Jean-Marc Rigot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer
Laurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy
Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway
Laurence Gamelin, Olivier Capitain, Alain Morel, et al.
The Lancet. Oncology
|
February 3, 2024
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
Kris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, et al.
Blood Advances
|
April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
Sarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Seminars in Oncology
|
November 8, 2002
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures
Erick Gamelin, Laurence Gamelin, Laura Bossi, et al.
Bulletin Du Cancer
|
February 24, 2006
[Oxaliplatin neurotoxicity]
Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
International Journal of Hematology
|
April 17, 2016
Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies
Wendy J Langeberg, W Marieke Schoonen, Melissa Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 19, 2008
Recurrent priapism related to oxaliplatin infusion
Antoine Adenis, Audrey Mailliez, Jean-Marc Rigot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer
Laurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy
Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway
Laurence Gamelin, Olivier Capitain, Alain Morel, et al.
The Lancet. Oncology
|
February 3, 2024
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
Kris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, et al.
Blood Advances
|
April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
Sarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Page
of 1